Vimarsana
Biggest News Aggregation in the World

Page 4 - Mark Neumann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Neumann Today - Breaking & Trending Today

Regal Investment Advisors LLC Acquires 3,789 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Vimarsana News

Regal Investment Advisors LLC Acquires 3,789 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Regal Investment Advisors LLC lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 39.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,424 shares of the biopharmaceutical company’s stock after acquiring an additional 3,789 shares during the period. […]

Source: wkrb13.com
Traders Buy High Volume of Call Options on Intra-Cellular Therapies (NASDAQ:ITCI) - Vimarsana News

Traders Buy High Volume of Call Options on Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) saw some unusual options trading activity on Friday. Investors purchased 2,832 call options on the company. This represents an increase of approximately 901% compared to the average daily volume of 283 call options. Analysts Set New Price Targets ITCI has been the subject of a number of […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $78.67 Average Price Target from Brokerages - Vimarsana News

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $78.67 Average Price Target from Brokerages

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the […]

Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Cut to $76.00 - Vimarsana News

Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Cut to $76.00

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its price target lowered by equities researchers at Royal Bank of Canada from $77.00 to $76.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price would indicate a […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2023 Earnings Call Transcript - Vimarsana News

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2023 Earnings Call Transcript

Operator: Thank you for standing by, and welcome to the Intra-Cellular Therapies 3Q 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.